PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, recently announced that it has signed a contract with Alcami Corporation, a global pharmaceutical contract development and manufacturing organization (CDMO) with extensive experience in cGMP sterile fill-finish products and the handling of controlled substances, for the
PharmaTher is concentrating on developing a ketamine-based speciality product pipeline to supplement its internal product pipeline, which includes rare and near-rare neurological illnesses like Parkinson’s disease and ALS (Lou Gehrig’s disease). PharmaTher’s ability to manufacture and provide ketamine medicines in a variety of dosage forms allows it to not only ensure delivery of its product pipeline, but also to collaborate on other value-added projects. The Company anticipates forming partnerships with research labs, ketamine clinics, and pharmaceutical companies that are looking for a reliable supply of cGMP ketamine and ketamine products for their current portfolios, exploring alternative dose forms for a variety of existing indications, and requiring assistance to develop and commercialize specific ketamine products for new indications. PharmaTher’s unique ketamine medicinal product(s) are projected to be ready for FDA Phase 3 clinical trials and commercial use in H2-2022.
Alcami announced a $31 million investment in its sterile research and production unit in Charleston, SC, on September 29, 2021, which will significantly boost its fill-finish and lyophilization capacity. PharmaTher’s global ketamine product development and commercialization efforts will be aided by this expansion.
“PharmaTher is evolving to become a leader in ketamine-based solutions for mental health, neurological and pain disorders, and partnering with Alcami as our exclusive manufacturer for the clinical and commercial supply of ketamine allows us to fulfill our objectives in serving these large markets and future partnering opportunities globally,” said Fabio Chianelli, CEO of PharmaTher.
